Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Provided By GlobeNewswire
Last update: Nov 7, 2024
Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens
Correlation observed between disease-free survival (“DFS”) and T cell response
Read more at globenewswire.com
